|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Tipifarnib>> Market Analysis Reports |
Market Analysis Reports of Tipifarnib |
|
Tipifarnib (CAS 192185-68-5) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Tipifarnib Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Tipifarnib (CAS 192185-72-1) December 2024 CAS 192185-72-1 Tipifarnib Chemical Report & Database ... listed. The substance covered (Tipifarnib) are classified by the ... & Database definitions: Name: Tipifarnib: Tipifarnib; Zarnestra; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H- ... Chemical or Reaction Intermediate The Tipifarnib Report & Database gives Market ... Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020 ... cell lymphoma Emerging Drugs Tipifarnib: Kura Oncology Tipifarnib, is a potent and highly ... Company’s lead drug candidate, tipifarnib, for the treatment of adult patients ... Arno Therapeutics Key Products Tipifarnib Dasatinib Enasidenib Azacitidine AUTO4 ... FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021 ... FTase inhibitor Emerging Drugs Tipifarnib: Kura Oncology Tipifarnib is an oral investigational farnesyl ... quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the ... Eiger Biopharmaceuticals Key Products Tipifarnib Lonafarnib FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2022 ... FTase inhibitor Emerging Drugs Tipifarnib: Kura Oncology Tipifarnib is an oral investigational farnesyl ... quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the ... Eiger Biopharmaceuticals Key Products Tipifarnib Lonafarnib Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review ... Chronic myelomonocytic leukaemia - Pipeline Insight, 2021 ... NMS 03592088 Guadecitabine Pevonedistat Cusatuzumab Tipifarnib Ruxolitinib Venetoclax SNS-301 Cobimetinib ... T cell lymphoma - Pipeline Insight, 2021 ... -N Valemetostat Tosylate TQ-B3525 TQ-B3101 Tislelizumab Tipifarnib SP-02L SP-02 Sintilimab SHC014748M SGN-35 RP6530 ... KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031 The NRAS, HRAS and KRAS market is expected to reach USD 73 million in 2021 and anticipated to grow at a CAGR of 53.6% during the forecast period 2021-2031 In 2020, an estimated 10 million reported fatalities were attributed to cancer, standing as a ... |